Guselkumab safely improved clinical outcomes in biologic-naive patients with psoriatic arthritis.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 32687763.
- Also identified by DOI 10.7326/ACPJ202007210-007.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mease PJ, Rahman P, Gottlieb AB, et al. <b>Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.</b> Lancet. 2020;395:1126-36. 32178766.
Medical subject headings
- Arthritis, Psoriatic
- Biological Products